Deuterated colony stimulating factor-1 receptor (CSF-1R) inhibitors

A compound of Formula (I′):

• and/or stereoisomers, optical isomers, racemic and diastereomeric mixtures, and/or pharmaceutically acceptable salts thereof, wherein:
• the dashed lines represent optional double bonds;
• A is selected from H and D;
• X3′ is CR3′ wherein R3′ is selected from H and D;
• X4′ is CR4′ wherein R4′ is selected from H, and D;
• X5′ is CR5′ wherein R5′ is selected from H and D;
• T1, T2, and T3 are each independently selected from N or CR′;
• wherein each R10 is independently selected from H, D, (C1-C10)alkyl, (C3-C10)cycloalkyl, (C1-C10)alkylamine, ((C1-C10)alkyl)2amine, (C2-C10)alkynylamine, (C1-C10)alkyl-C(O)O—, COOH—(C1-C10)alkyl-, COOH—(C3-C10)cycloalkyl-, (C1-C10)alkoxy-, R10A—(C1-C10)alkyl-, R10A—(C1-C10)alkylamine, R10A-((C1-C10)alkyl)2amine, R10A—(C2-C10)alkynylamine, R10A—C(O)—, R10A—(C1-C10)alkyl-C(O)O—, R10A—(C1-C10)alkoxy-, HO—, and halo, cyano, H2N—, (CH3)HN—, (CH3)2N—, R10AR11N—, R10AR11N(O)C—, R10A(R11C(O))N—, R10AR11NC(O)O—, R10AC(O)—, R10AR11NC(O)R10AN—, (C1-C10)alkyl-OC(O)R10AN—, F3C—, F2HC—, CH3F2C—, FH2C—, CH3FHC—, (CH3)2FC—;
• wherein R10A and R11 are each independently selected from H, D, (C1-C10)alkyl, (C1-C10)alkylamine, ((C1-C10)alkyl)2amine, (C1-C3)alkynylamine, (C1-C10)alkyl-C(O)O—, COOH—(C1-C10)alkyl, (C1-C10)alkoxy-, (C1-C10)alkoxy-(C1-C10)alkyl-, HO—, halo, (CH3)2N—, and H2N—;
• wherein each (C1-C10)alkyl are further optionally substituted by one to four groups selected from D, (C1-C10)alkyl, (C1-C10)alkylamine, ((C1-C10)alkyl)2amine, (C1-C10)alkoxy-, (C1-C10)alkoxy-(C1-C10)alkyl-, HO—, halo, or H2N—
• Y1 is O, NR12, or CR12R13,
• wherein R12 is absent or R12 and R13 are each independently selected from H, D, (C1-C10)alkyl, (C1-C10)alkylamine, ((C1-C10)alkyl)2amine, (C1-C3)alkynylamine, (C1-C10)alkoxy-, (C1-C10)alkoxy-(C1-C10)alkyl-, HO—, halo, and H2N—;
• R1 and R2 are each independently selected from H, D, (C1-C10)alkyl, HO—, halo, and H2N;
• R5 is absent or selected from the group H, D, (C1-C10)alkyl, HO—, halo, and H2N—;
• and
• R6 is selected from the group D, (C1-C10)alkyl, (C3-C10)cycloalkyl, (C2-C9)heteroaryl, (C1-C10)alkylamine, ((C1-C10)alkyl)2amine, R14-(C3-C10)cycloalkyl, R14-(C6-C14)aryl, R14-(C2-C9)heteroaryl, and R14-(C1-C10)alkylamine;
• wherein R14 is each independently selected from H, D, (C1-C10)alkyl, (C3-C10)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-C14)aryl, (C2-C9)heteroaryl, (C1-C10)alkylamine, ((C1-C10)alkyl)2amine, (C1-C10)alkoxy-, HO—, F2HC—O—, halo, (CH3)2N—, F3C—C(O)—, F3C—, and F2HC—;
• wherein each (C1-C10)alkyl, (C6-C14)aryl, (C2-C9)heteroaryl, (C3-C10)cycloalkyl, or (C2-C9)heterocycloalkyl are further optionally substituted by one to four groups selected from (C1-C10)alkyl, (C3-C10)cycloalkyl, (C2-C9)heterocycloalkyl, (C6-C14)aryl, (C2-C9)heteroaryl, HO—, halo, or H2N—;
• and
• Z1 is selected from H, halo, and (C1-C10)alkyl;
• Y2 is O, NR17, or CR17R18;
• wherein R17 is absent or R17 and R18 are each independently selected from H, (C1-C10)alkyl, HO—, halo, or H2N—;
• wherein at least one of A, R3′, R4′, and R5′ is D.